Zenocutuzumab Earns FDA Priority Review in NRG1+ NSCLC, Pancreatic Cancer
Data from the phase 1/2 eNRGy trial support the biologics license application for zenocutuzumab in NRG1-positive NSCLC and PDAC.
Data from the phase 1/2 eNRGy trial support the biologics license application for zenocutuzumab in NRG1-positive NSCLC and PDAC.
Antibody libraries, inspired by the Review on p399.
The addition of ibrutinib to chemoimmunotherapy induction with ASCT improved rates of failure-free survival in younger patients with mantle cell lymphoma.
Find the best home for your paper, quickly and easily. Take advantage of Elsevier’s Article Transfer Service.We understand that authors are unique, and each …
Rett syndrome is a multisystem disorder that primarily affects girls; multiple loss-of-function mutations to the MECP2 gene are the cause of this rare disease.
Jameel Muzaffar, MD, discusses findings from the phase 2 portion of the FLX475-02 study examining tivumecirnon plus pembrolizumab in HNSCC.
Home to the journal Oncology, Cancer Network provides research and opinion on the screening, early detection, diagnosis, treatment, and prevention of cancers.
Amanda Cali, Co-founder of Tin Soldiers Global, discusses how the organization helps find patients with FOP and other rare diseases.
Aravindhan Veerapandiyan, MD, discusses the AFFINITY clinical trial testing the safety and efficacy of RGX-202 for patients with DMD.
The XIX International Symposium on Amyloidosis (ISA) will be held in Rochester, MN, between May 26-30, 2024. This meeting will cover a variety of amyloidosis…
Timothy Yap, MBBS, PhD, FRCP, discusses encouraging data seen with the first-in-class PARP1 selective inhibitor saruparib in solid tumors and how the agent is being…